Silver Lake proposes to fully characterize mAb against 6 targets produced in their three concurrent Phase 1 projects that are relevant in models of disease and inflammation, determine their usability in multiple assay types, develop user protocols for each assay type and mAb, produce quality-controlled reagents, produce multiple conjugates for each mAb, and make all reagents available for the research community.